AB1111 SUSTAINED RESPONSE TO GUSELKUMAB REGARDLESS OF BASELINE DEMOGRAPHIC, DISEASE, AND MEDICATION CHARACTERISTICS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TNF INHIBITORS: RESULTS FROM A PHASE 3B TRIAL
Mcinnes, I, Sewerin, P, Sharaf, M, Efficace, M, Shawi, M, Perate, M, Zimmermann, M, Coates, L
Published in Annals of the rheumatic diseases (01.06.2023)
Published in Annals of the rheumatic diseases (01.06.2023)
Get full text
Journal Article
The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial
Clift, P, Berger, F, Sondergaard, L, Antonova, P, Disney, P, Nicolarsen, J, Thambo, J B, Tomkiewicz Pajak, L, Wang, J K, Schophuus Jensen, A, Burgess, G, Efficace, M, Friberg, M, Lassen, C, d'Udekem, Y
Published in European heart journal (03.10.2022)
Published in European heart journal (03.10.2022)
Get full text
Journal Article
P5462Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomised controlled MAESTRO study
Galie, N., Landzberg, M., Beghetti, M., Berger, R.M., Efficace, M., Gesang, S., Papadakis, K., Gatzoulis, M.A.
Published in European heart journal (01.08.2017)
Published in European heart journal (01.08.2017)
Get full text
Journal Article